Gender-affirming hormonal therapy induces a gender-concordant fecal metagenome transition in transgender individuals
Timur Liwinski,
Matthias K. Auer,
Johanna Schröder,
Ina Pieknik,
Christian Casar,
Dorothee Schwinge,
Lara Henze,
Günter K. Stalla,
Undine E. Lang,
Alina von Klitzing,
Peer Briken,
Thomas Hildebrandt,
Jeanne C. Desbuleux,
Sarah V. Biedermann,
Paul-Martin Holterhus,
Corinna Bang,
Christoph Schramm,
Johannes Fuss
Affiliations
Timur Liwinski
Clinic for Adult Psychiatry, University Psychiatric Clinics, University of Basel
Matthias K. Auer
Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München
Johanna Schröder
Department of Psychology, Institute for Clinical Psychology and Psychotherapy, Medical School Hamburg
Ina Pieknik
Institute of Forensic Psychiatry and Sex Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen
Christian Casar
First Department of Medicine, University Medical Centre Hamburg-Eppendorf (UKE)
Dorothee Schwinge
First Department of Medicine, University Medical Centre Hamburg-Eppendorf (UKE)
Lara Henze
First Department of Medicine, University Medical Centre Hamburg-Eppendorf (UKE)
Günter K. Stalla
Medizinische Klinik and Poliklinik IV, Klinikum der Universität München, LMU München
Undine E. Lang
Clinic for Adult Psychiatry, University Psychiatric Clinics, University of Basel
Alina von Klitzing
Institute for Sex Research, Sexual Medicine and Forensic Psychiatry, University Medical Center Hamburg-Eppendorf
Peer Briken
Institute for Sex Research, Sexual Medicine and Forensic Psychiatry, University Medical Center Hamburg-Eppendorf
Thomas Hildebrandt
Department of Gynecology and Obstetrics, CCC Erlangen EMN, Friedrich Alexander University
Jeanne C. Desbuleux
Institute of Forensic Psychiatry and Sex Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen
Sarah V. Biedermann
Department of Psychiatry and Psychotherapy, Social and Emotional Neuroscience Group, Center for Psychosocial Medicine, University Medical Center Hamburg-Eppendorf
Paul-Martin Holterhus
Division of Pediatric Endocrinology and Diabetes, Department of Children and Adolescent Medicine I, University Hospital of Schleswig-Holstein, Campus Kiel/Christian-Albrechts University of Kiel
Corinna Bang
Institute of Clinical Molecular Biology, Christian-Albrechts-University Kiel, University Hospital Schleswig-Holstein
Christoph Schramm
First Department of Medicine, University Medical Centre Hamburg-Eppendorf (UKE)
Johannes Fuss
Institute of Forensic Psychiatry and Sex Research, Center for Translational Neuro- and Behavioral Sciences, University of Duisburg-Essen
Abstract Background Limited data exists regarding gender-specific microbial alterations during gender-affirming hormonal therapy (GAHT) in transgender individuals. This study aimed to investigate the nuanced impact of sex steroids on gut microbiota taxonomy and function, addressing this gap. We prospectively analyzed gut metagenome changes associated with 12 weeks of GAHT in trans women and trans men, examining both taxonomic and functional shifts. Methods Thirty-six transgender individuals (17 trans women, 19 trans men) provided pre- and post-GAHT stool samples. Shotgun metagenomic sequencing was used to assess the changes in gut microbiota structure and potential function following GAHT. Results While alpha and beta diversity remained unchanged during transition, specific species, including Parabacteroides goldsteinii and Escherichia coli, exhibited significant abundance shifts aligned with affirmed gender. Overall functional metagenome analysis showed a statistically significant effect of gender and transition (R 2 = 4.1%, P = 0.0115), emphasizing transitions aligned with affirmed gender, particularly in fatty acid-related metabolism. Conclusions This study provides compelling evidence of distinct taxonomic and functional profiles in the gut microbiota between trans men and women. GAHT induces androgenization in trans men and feminization in trans women, potentially impacting physiological and health-related outcomes. Trial registration Clinicaltrials.gov NCT02185274.